SUNPG 1623Alternative Names: SUNPG 1623 I; SUNPG 1623 II; SUNPG 1623 III; SUNPG 1623 IV; SUNPG1623
Latest Information Update: 13 Dec 2016
At a glance
- Originator Sun Pharmaceutical Industries
- Class Anti-inflammatories
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase Unknown Psoriatic arthritis
Most Recent Events
- 07 Dec 2016 Sun Pharma Global FZE plans a phase IIb trial for Psoriatic arthritis (Adjunctive treatment) in USA (NCT02980692)
- 30 Nov 2016 Investigation in Psoriatic arthritis in USA (unspecified route)